• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Implementing a digital clinical decision support tool for side effects of antipsychotics: a focus group study.实施抗精神病药副作用的数字化临床决策支持工具:一项焦点小组研究。
Evid Based Ment Health. 2019 May;22(2):56-60. doi: 10.1136/ebmental-2019-300086. Epub 2019 Apr 15.
2
Developing STEP-SE: A Qualitative Usability Study of a Novel Patient-Reported Outcomes Tool for Managing Side Effects in Shared Decision-Making for Schizophrenia Spectrum Disorder Care.开发 STEP-SE:用于管理精神分裂症谱系障碍护理中共享决策副作用的新型患者报告结局工具的定性可用性研究。
Health Expect. 2024 Dec;27(6):e70019. doi: 10.1111/hex.70019.
3
A web-based clinical decision tool to support treatment decision-making in psychiatry: a pilot focus group study with clinicians, patients and carers.一种支持精神病学治疗决策的基于网络的临床决策工具:一项针对临床医生、患者和护理人员的试点焦点小组研究。
BMC Psychiatry. 2017 Jul 21;17(1):265. doi: 10.1186/s12888-017-1406-z.
4
Experiences of psychotropic medication use and decision-making for adults with intellectual disability: a multistakeholder qualitative study in the UK.成年人智力残疾者使用精神药物的经历和决策:英国多方利益攸关者定性研究。
BMJ Open. 2019 Nov 27;9(11):e032861. doi: 10.1136/bmjopen-2019-032861.
5
Consultant psychiatrists' experiences of and attitudes towards shared decision making in antipsychotic prescribing, a qualitative study.精神科顾问医生在抗精神病药物处方中对共同决策的体验与态度:一项定性研究
BMC Psychiatry. 2014 May 1;14:127. doi: 10.1186/1471-244X-14-127.
6
Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia.基于证据的抗精神病药物选择共享决策辅助工具(SDM-assistant):一项针对住院精神分裂症患者的群组随机试验方案。
BMC Psychiatry. 2022 Jun 17;22(1):406. doi: 10.1186/s12888-022-04036-5.
7
Switching antipsychotics to support the physical health of people with severe mental illness: a qualitative study of healthcare professionals' perspectives.更换抗精神病药物以支持重度精神疾病患者的身体健康:一项关于医疗保健专业人员观点的定性研究
BMJ Open. 2021 Feb 26;11(2):e042497. doi: 10.1136/bmjopen-2020-042497.
8
Decision Support Tool to Improve Decision-Making for HIV Pre-Exposure Prophylaxis (PrEP): Development Process and Alpha Testing.用于改善 HIV 暴露前预防 (PrEP) 决策的决策支持工具:开发过程和 Alpha 测试。
JMIR Form Res. 2024 Oct 11;8:e57348. doi: 10.2196/57348.
9
Adaptation and Implementation of a Shared Decision-Making Tool From One Health Context to Another: Partnership Approach Using Mixed Methods.从一个健康背景到另一个健康背景的共享决策工具的调整和实施:使用混合方法的伙伴关系方法。
J Med Internet Res. 2023 Jul 5;25:e42551. doi: 10.2196/42551.
10
Making decisions about antipsychotics: a qualitative study of patient experience and the development of a decision aid.抗精神病药物决策:一项关于患者体验和决策辅助工具开发的定性研究。
BMC Psychiatry. 2019 Oct 23;19(1):309. doi: 10.1186/s12888-019-2304-3.

引用本文的文献

1
From Idealist to Realist-Designing and Implementing Shared Decision-Making Interventions in the Choice of Antipsychotic Prescription in People Living With Psychosis (SHAPE): A Realist Review (Part 2-Designing SDM Interventions: Optimizing Design and Local Implementation).从理想主义者到现实主义者——为精神病患者抗精神病药物处方选择设计并实施共享决策干预措施(SHAPE):一项现实主义综述(第2部分——设计共享决策干预措施:优化设计与本地实施)
Schizophr Bull. 2025 Jul 7;51(4):932-948. doi: 10.1093/schbul/sbaf059.
2
Do Decision Support Tools Decrease the Prevalence of Hospital-Acquired Venous Thromboembolisms When Compared to Clinical Judgement? A Single-Center Pre-Post Study.与临床判断相比,决策支持工具是否能降低医院获得性静脉血栓栓塞症的发生率?一项单中心前后对照研究。
J Clin Med. 2024 Jun 30;13(13):3854. doi: 10.3390/jcm13133854.
3
On the Road to Individualizing Pharmacotherapy for Adolescents and Adults with Schizophrenia - Results from an Expert Consensus Following the Delphi Method.青少年和成人精神分裂症个体化药物治疗之路——德尔菲法专家共识结果
Neuropsychiatr Dis Treat. 2024 May 24;20:1139-1152. doi: 10.2147/NDT.S456163. eCollection 2024.
4
Transdiagnostic clustering and network analysis for questionnaire-based symptom profiling and drug recommendation in the UK Biobank and a Korean cohort.基于问卷的症状分析和药物推荐的英国生物库和韩国队列的跨诊断聚类和网络分析。
Sci Rep. 2024 Feb 24;14(1):4500. doi: 10.1038/s41598-023-49490-7.
5
Shared Decision Making Assistant (SDMA) and other digital tools for choosing antipsychotics in schizophrenia treatment.共享决策辅助工具(SDMA)及其他用于精神分裂症治疗中选择抗精神病药物的数字工具。
Eur Arch Psychiatry Clin Neurosci. 2023 Dec;273(8):1629-1631. doi: 10.1007/s00406-023-01712-9.
6
Informing the development of a decision aid: Expectations and wishes from service users and psychiatrists towards a decision aid for antipsychotics in the inpatient setting.为决策辅助工具的开发提供信息:住院环境中抗精神病药物决策辅助工具的服务使用者和精神科医生的期望和愿望。
Health Expect. 2023 Jun;26(3):1327-1338. doi: 10.1111/hex.13749. Epub 2023 Mar 14.
7
Stakeholder Perspectives of Clinical Artificial Intelligence Implementation: Systematic Review of Qualitative Evidence.利益相关者对临床人工智能实施的观点:定性证据的系统评价。
J Med Internet Res. 2023 Jan 10;25:e39742. doi: 10.2196/39742.
8
Psychometric evaluation of the Decision Support Tool for Functional Independence in community-dwelling older people.社区居住老年人功能独立性决策支持工具的心理测量评估
J Popul Ageing. 2022 Mar 29:1-23. doi: 10.1007/s12062-022-09361-x.
9
Ensuring patient and public involvement in the transition to AI-assisted mental health care: A systematic scoping review and agenda for design justice.确保患者和公众参与向人工智能辅助心理健康护理的过渡:系统范围界定综述和设计正义议程。
Health Expect. 2021 Aug;24(4):1072-1124. doi: 10.1111/hex.13299. Epub 2021 Jun 12.
10
Shared and Supported Decision Making in Medication in a Mental Health Setting: How Far Have We Come?精神卫生环境中的药物共享和共同决策:我们已经走了多远?
Community Ment Health J. 2021 Nov;57(8):1566-1578. doi: 10.1007/s10597-021-00780-2. Epub 2021 Feb 5.

本文引用的文献

1
Pragmatic Neuroethics: Lived Experiences as a Source of Moral Knowledge.实用神经伦理学:作为道德知识来源的生活经历
Camb Q Healthc Ethics. 2018 Oct;27(4):578-589. doi: 10.1017/S0963180118000105.
2
Providing the most appropriate care to our patients.为我们的患者提供最恰当的护理。
Evid Based Ment Health. 2019 Feb;22(1):1-2. doi: 10.1136/ebmental-2019-300080. Epub 2019 Jan 21.
3
Common pitfalls and mistakes in the set-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article.网络荟萃分析中设定、分析和结果解释的常见陷阱和错误:临床医生在已发表文章中应注意的问题。
Evid Based Ment Health. 2017 Aug;20(3):88-94. doi: 10.1136/eb-2017-102753. Epub 2017 Jul 24.
4
A web-based clinical decision tool to support treatment decision-making in psychiatry: a pilot focus group study with clinicians, patients and carers.一种支持精神病学治疗决策的基于网络的临床决策工具:一项针对临床医生、患者和护理人员的试点焦点小组研究。
BMC Psychiatry. 2017 Jul 21;17(1):265. doi: 10.1186/s12888-017-1406-z.
5
Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.60 年来抗精神病药物治疗急性精神分裂症的安慰剂对照试验:系统评价、贝叶斯荟萃分析和疗效预测因素的荟萃回归。
Am J Psychiatry. 2017 Oct 1;174(10):927-942. doi: 10.1176/appi.ajp.2017.16121358. Epub 2017 May 25.
6
Network meta-analyses should be the highest level of evidence in treatment guidelines.网状荟萃分析应成为治疗指南中最高级别的证据。
Eur Arch Psychiatry Clin Neurosci. 2016 Sep;266(6):477-80. doi: 10.1007/s00406-016-0715-4.
7
Innovative approaches to bipolar disorder and its treatment.双相情感障碍及其治疗的创新方法。
Ann N Y Acad Sci. 2016 Feb;1366(1):76-89. doi: 10.1111/nyas.13048.
8
Ketamine and other glutamate receptor modulators for depression in adults.氯胺酮及其他用于成人抑郁症治疗的谷氨酸受体调节剂。
Cochrane Database Syst Rev. 2015 Sep 23(9):CD011612. doi: 10.1002/14651858.CD011612.pub2.
9
Precision medicine--personalized, problematic, and promising.精准医学——个性化、存在问题且充满希望。
N Engl J Med. 2015 Jun 4;372(23):2229-34. doi: 10.1056/NEJMsb1503104. Epub 2015 May 27.
10
Tools to Promote Shared Decision Making in Serious Illness: A Systematic Review.促进重症患者共同决策的工具:一项系统综述。
JAMA Intern Med. 2015 Jul;175(7):1213-21. doi: 10.1001/jamainternmed.2015.1679.

实施抗精神病药副作用的数字化临床决策支持工具:一项焦点小组研究。

Implementing a digital clinical decision support tool for side effects of antipsychotics: a focus group study.

机构信息

Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK.

Department of Psychiatry, University of Oxford, Oxford, UK.

出版信息

Evid Based Ment Health. 2019 May;22(2):56-60. doi: 10.1136/ebmental-2019-300086. Epub 2019 Apr 15.

DOI:10.1136/ebmental-2019-300086
PMID:30987972
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10270420/
Abstract

BACKGROUND

In medicine, algorithms can inform treatment decisions by combining the most up-to-date evidence about side effect profiles of medications, which are comparable in efficacy. Their use provides opportunities for improved shared clinician-patient decision-making when initiating therapy. We designed a decision support tool (DST) that incorporated the latest evidence regarding antipsychotic side effects. The tool allowed patients to select one side effect commonly associated with antipsychotics that they wished to avoid; the tool then provided a list of suggested medications and ones to avoid.

OBJECTIVE

To explore qualitatively the acceptability and usefulness of the DST from the perspectives of patients and psychiatrists.

METHODS

This qualitative study took place at a mental health and community hospital in Oxford, UK, in 2018. Four patients/carers and four psychiatrists were recruited to two focus groups to explore their perceptions of the tool. Data were thematically analysed.

FINDINGS

Findings demonstrated a high degree of acceptability and potential usability of the DST for patients and psychiatrists. The main themes to emerge relating to the DST were 'prescribing preferences and practices', 'consideration and awareness of side effects', 'app content, layout and accessibility', 'influence on clinical practice' and 'role in decision-making'.

CONCLUSIONS

A proof-of-concept clinical study will incorporate the recommendations produced from the findings into the tool's design.

CLINICAL IMPLICATIONS

Digital DSTs provide opportunities for the most up-to-date information on medication side effects to be used as the basis for shared clinician-patient decision-making. This tool has the potential to improve adherence to psychiatric medication, with benefits to clinical outcomes and healthcare resourcing.

摘要

背景

在医学领域,算法可以通过结合关于药物副作用的最新证据来为治疗决策提供信息,这些证据在疗效上是可比的。当开始治疗时,它们的使用为改善临床医生和患者共同决策提供了机会。我们设计了一个决策支持工具(DST),其中包含了关于抗精神病药副作用的最新证据。该工具允许患者选择他们希望避免的一种常见的抗精神病药副作用;然后,该工具提供了一份建议药物和避免药物的清单。

目的

从患者和精神科医生的角度定性探索 DST 的可接受性和有用性。

方法

这项定性研究于 2018 年在英国牛津的一家心理健康和社区医院进行。招募了 4 名患者/照顾者和 4 名精神科医生参加两个焦点小组,以探讨他们对该工具的看法。数据进行了主题分析。

结果

研究结果表明,患者和精神科医生对 DST 的接受程度和潜在可用性都很高。与 DST 相关的主要主题包括“处方偏好和实践”、“考虑和意识到副作用”、“应用程序的内容、布局和可访问性”、“对临床实践的影响”和“在决策中的作用”。

结论

一项概念验证临床研究将把从研究结果中提出的建议纳入到工具的设计中。

临床意义

数字 DST 为使用药物副作用的最新信息作为临床医生和患者共同决策的基础提供了机会。该工具有可能提高对精神科药物的依从性,从而改善临床结果和医疗资源利用。